Cirrhosis is a heterogeneous disease with a high mortality, It is the fifth-leading cause of adult deaths and classified in to in two main prognostic stages: compensated and decompensated cirrhosis, depending on the presence or absence of clinically evident decompensating events (specifically ascites, VH, and encephalopathy. Gastro esophageal varices are present in approximately 50% of patients with cirrhosis, but this depends on the clinical stage. In patients with CC, GEVare present in 30%-40%, whereas they can be present in up to 85% of patients with decompensated cirrhosis. There are two approaches for treating GEV: primary prophylaxis to manage bleeding or emergency treatment for bleeding followed by secondary prophylaxis. Treatment methods can be classified into two categories: 1) Those used to decrease portal pressure, such as medication (i.e., nonselective β-blockers), radiological intervention [transjugular intrahepatic portosystemic shunt (TIPS)] or a surgical approach (i.e., portacaval shunt), and 2) Those used to obstruct GEV, such as endoscopy [endoscopic variceal ligation (EVL), endoscopic injection sclerotherapy (EIS), and tissue adhesive injection] or radiological intervention [balloon-occluded retrograde transvenous obliteration (BRTO)]. Clinicians should choose a treatment method based on an understanding of its efficacy and limitations.